Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers

Evogliptin (EV) is a novel dipeptidyl peptidase‐4 inhibitor (DPP4i) for glycemic control in patients with type 2 diabetes mellitus (T2DM). This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between EV and sodium glucose cotransporter‐2 inhibitors (SGLT2i) in healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dasohm, Choi, Minkyu, Jin, Byung Hak, Hong, Taegon, Kim, Choon Ok, Yoo, Byung Won, Park, Min Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432875/
https://www.ncbi.nlm.nih.gov/pubmed/37282359
http://dx.doi.org/10.1111/cts.13566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432875/
https://www.ncbi.nlm.nih.gov/pubmed/37282359
http://dx.doi.org/10.1111/cts.13566

Ejemplares similares